These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22799577)

  • 1. Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study.
    Castillo N; García-García P; Rivero A; Jiménez-Sosa A; Macía M; Getino MA; Méndez ML; García-Pérez J; Navarro-González JF
    BMC Nephrol; 2012 Jul; 13():60. PubMed ID: 22799577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan.
    Fukuma S; Yamaguchi T; Hashimoto S; Nakai S; Iseki K; Tsubakihara Y; Fukuhara S
    Am J Kidney Dis; 2012 Jan; 59(1):108-16. PubMed ID: 21890255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience
.
    Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
    Clin Nephrol; 2018 Oct; 90(4):276-285. PubMed ID: 30049300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients.
    Kwon O; Jang HM; Jung HY; Kim YS; Kang SW; Yang CW; Kim NH; Choi JY; Cho JH; Kim CD; Kim YL; Park SH;
    PLoS One; 2015; 10(10):e0140241. PubMed ID: 26452232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study.
    Galle JC; Addison J; Suranyi MG; Claes K; Di Giulio S; Guerin A; Herlitz H; Kiss I; Farouk M; Manamley N; Wirnsberger G; Winearls C
    Nephrol Dial Transplant; 2016 Dec; 31(12):2073-2085. PubMed ID: 27190334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009.
    Regidor D; McClellan WM; Kewalramani R; Sharma A; Bradbury BD
    Nephrol Dial Transplant; 2011 May; 26(5):1583-91. PubMed ID: 20861195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.
    Minutolo R; Bolasco P; Chiodini P; Sposini S; Borzumati M; Abaterusso C; Mele AA; Santoro D; Canale V; Santoboni A; Filiberti O; Fiorini F; Mura C; Imperiali P; Borrelli S; Russo L; De Nicola L; Russo D
    Clin Drug Investig; 2017 Oct; 37(10):965-973. PubMed ID: 28779268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of a change in erythropoiesis-stimulating agent dose during hospitalization and subsequent hemoglobin levels and transfusions in hemodialysis patients.
    Wong BC; Ravani P; Manns BJ; Lewin A; Zhang X; Chin R; Hemmelgarn BR; Tonelli M; Oliver MJ; Quinn RR
    Am J Kidney Dis; 2013 Nov; 62(5):947-52. PubMed ID: 23856380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysis.
    Khan I; Krishnan M; Kothawala A; Ashfaq A
    BMC Nephrol; 2011 May; 12():22. PubMed ID: 21595975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients.
    Duong U; Kalantar-Zadeh K; Molnar MZ; Zaritsky JJ; Teitelbaum I; Kovesdy CP; Mehrotra R
    Am J Nephrol; 2012; 35(2):198-208. PubMed ID: 22286821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiation of erythropoiesis-stimulating agents and outcomes: a nationwide observational cohort study in anaemic chronic kidney disease patients.
    Evans M; Carrero JJ; Bellocco R; Barany P; Qureshi AR; Seeberger A; Jacobson SH; Hylander-Rössner B; Rotnitzky A; Sjölander A
    Nephrol Dial Transplant; 2017 Nov; 32(11):1892-1901. PubMed ID: 27672090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.
    Ingrasciotta Y; Lacava V; Marcianò I; Giorgianni F; Tripepi G; D' Arrigo G; Chinellato A; Ugo Tari D; Santoro D; Trifirò G
    BMC Nephrol; 2019 Sep; 20(1):359. PubMed ID: 31521117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
    Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients.
    Bradbury BD; Critchlow CW; Weir MR; Stewart R; Krishnan M; Hakim RH
    Nephrol Dial Transplant; 2009 Mar; 24(3):919-25. PubMed ID: 18840893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
    Bastos K; Lucarelli LA; De Francesco-Daher E; Filho RP; Henríquez C; Espinoza B; Villanueva I; Schwedt E; Schiavelli R; Correa-Rotter R
    Int Urol Nephrol; 2013 Oct; 45(5):1355-64. PubMed ID: 22990412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-averaged hemoglobin values, not hemoglobin cycling, have an impact on outcomes in pediatric dialysis patients.
    Bakkaloğlu SA; Kandur Y; Serdaroğlu E; Noyan A; Bayazıt AK; Taşdemir M; Özlü SG; Özçelik G; Dursun İ; Alparslan C; Akcaboy M; Atikel YÖ; Parmaksız G; Atmış B; Sever L
    Pediatr Nephrol; 2018 Nov; 33(11):2143-2150. PubMed ID: 30105415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
    Bae MN; Kim SH; Kim YO; Jin DC; Song HC; Choi EJ; Kim YL; Kim YS; Kang SW; Kim NH; Yang CW; Kim YK
    PLoS One; 2015; 10(11):e0143348. PubMed ID: 26588085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.
    Ingrasciotta Y; Giorgianni F; Marcianò I; Bolcato J; Pirolo R; Chinellato A; Ientile V; Santoro D; Genazzani AA; Alibrandi A; Fontana A; Caputi AP; Trifirò G
    PLoS One; 2016; 11(5):e0155805. PubMed ID: 27187174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of mid-week hemoglobin measurement for anemia management in patients undergoing hemodialysis: a retrospective cohort study.
    Bae SY; Jeon JW; Kim SH; Baek CH; Jang JW; Yang WS; Kim SB; Park SK; Lee SK; Kim H
    BMC Nephrol; 2019 Aug; 20(1):295. PubMed ID: 31375077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.